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Abstract
Background: Coccidiosis caused by protozoans of genus Eimeria is a chicken parasitic disease of
great economical importance. Conventional disease control strategies depend on vaccination and
prophylactic use of anticoccidial drugs. Alternative solution to prevent and treat coccidiosis could
be provided by passive immunization using orally delivered neutralizing antibodies. We investigated
the possibility to mitigate the parasitic infection by feeding poultry with antibody expressing
transgenic crop seeds.
Results: Using the phage display antibody library, we generated a panel of anti-Eimeria  scFv
antibody fragments with high sporozoite-neutralizing activity. These antibodies were expressed
either transiently in agrobacteria-infiltrated tobacco leaves or stably in seeds of transgenic pea
plants. Comparison of the scFv antibodies purified either from tobacco leaves or from the pea
seeds demonstrated no difference in their antigen-binding activity and molecular form
compositions. Force-feeding experiments demonstrated that oral delivery of flour prepared from
the transgenic pea seeds had higher parasite neutralizing activity in vivo than the purified antibody
fragments isolated from tobacco. The pea seed content was found to protect antibodies against
degradation by gastrointestinal proteases (>100-fold gain in stability). Ad libitum feeding of chickens
demonstrated that the transgenic seeds were well consumed and not shunned. Furthermore,
feeding poultry with shred prepared from the antibody expressing pea seeds led to significant
mitigation of infection caused both by high and low challenge doses of Eimeria oocysts.
Conclusion: The results suggest that our strategy offers a general approach to control parasitic
infections in production animals using cost-effective antibody expression in crop seeds affordable
for the animal health market.
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Background
Coccidiosis is a diarrheal disease of chickens caused by
protozoan parasites of the genus Eimeria. It impairs mor-
tality, feed utilization and growth of poultry and causes
annual losses of US$ 2.4 billion to the poultry industry
worldwide [1]. Conventional disease control strategies
depend on vaccination and prophylactic use of anticoc-
cidial drugs. However, resistances against the anticoccidial
compounds have already spread and coccidiostats as feed
additives will be banned in Europe by the year 2012 [2].
Vaccination strategies with avirulent or attenuated Eimeria
strains have been routinely used for 50 years, but the large
scale production of parasites is relatively laborious and
expensive. Limited progress has been achieved towards
the development of subunit or recombinant vaccines, the
major hurdle being the identification of protective anti-
gens and the delivery (presentation) of the recombinant
vaccine to the chicken immune system [1,3,4].
As an alternative strategy, coccidiosis could be prevented
by oral delivery of antibodies that inhibit parasite inva-
sion. The complex life cycle of Eimeria comprises an exog-
enous phase in the environment during which the
excreted oocysts undergo sporulation. After infection via
ingestion of sporulated oocysts, an endogenous phase in
the chicken intestine consisting of asexual reproduction
(schizogony) and sexual differentiation (gamogony) takes
place, followed by fertilization and shedding of unsporu-
lated oocysts [5]. The key step in the disease process in the
chicken is the invasion of gut epithelial cells by the para-
site. Gut epithelium invasion is accomplished by sporo-
zoites and merozoites as the extracellular invasive stages
which represent an attractive target for orally applied
inhibitory antibodies. During the last years, numerous
monoclonal antibodies against Eimeria  antigens have
been generated, several of them showed an inhibitory
effect on sporozoite invasion in the cell culture [6-8]. Fur-
thermore, some monoclonal antibodies, administered
intravenously (i.v.) or intraperitoneally (i.p.) for passive
immunization, were able to reduce significantly the
oocyst output and/or the lesion scores in the chicken gut
[9,10].
There are a few major issues precluding use of mono-
clonal antibodies for preventive and curative passive
immunization of the animals against infectious diseases:
(i) the costs of antibody production and (ii) the costs of
treatment. The treatment costs could be significantly
reduced by switching from i.v. or i.p. route of administra-
tion to the oral delivery of the feed additives. However,
(iii) the natural antibodies per se are the serum proteins
which easily degrade in the gastrointestinal (GI) tract
before they reach their target. All mentioned issues have
been addressed in the present study. Using a phage dis-
play antibody library, we generated the anti-Eimeria anti-
body fragments with high sporozoite-neutralizing
activity. These antibodies were expressed in seeds of trans-
genic feed pea thus providing a cost-effective antibody
production platform affordable for the animal health
market. The pea seeds demonstrated the excellent anti-
body storage properties: dry seeds could be stored at room
temperature for long time periods without any loss of
antibody activity and they could withstand elevated tem-
peratures during the preparation of feed pellets. Moreo-
ver, pea seed content protects antibodies from
degradation in the GI tract. The animal experiments dem-
onstrated that ad libitum feeding of chickens with fodder
comprising the shred prepared from the antibody express-
ing pea seeds led to a protective and/or curative effect on
infection of chickens with Eimeria parasite.
Results
Generation of a phage display antibody library and 
selection of Eimeria-specific antibodies
To generate recombinant antibodies with Eimeria para-
site-neutralizing activity, mice were immunized with a
mixture containing purified parasite material (oocysts,
sporocysts and sporozoites) of five avian Eimeria species
(E. tenella, E. acervulina, E. necatrix, E. maxima and E. bru-
netti). Spleens of mice with the positive immune response
were used for mRNA extraction and generation of phage
displayed singe-chain Fv (scFv) antibody library of diver-
sity 5.5 × 107 individual clones. For isolation of antibody
fragments binding to Eimeria  proteins, soluble protein
extracts of oocysts, sporozoites and merozoites of E. ten-
ella (one of the most economically important Eimeria spe-
cies [1]) were used as complex antigens for panning of the
scFv library. After three rounds of panning, amplification,
and re-panning, 112 clones expressing scFv were obtained
that bound the oocyst extract, 64 clones which bound
sporozoite protein, 39 clones that bound membrane pro-
teins from oocysts and sporozoites and 67 clones that
bound merozoite proteins (Table 1). Sequence analyses
revealed that the selected clones comprise 97 individual
scFvs. ELISA demonstrated specific binding of all 97
selected scFv variants to immobilized Eimeria  antigens
with signals significantly higher than the background; 55
scFvs bound to oocyst proteins, 58 to sporozoite proteins
and 22 to merozoite proteins. Some scFvs showed specif-
icity to both oocyst and sporozoite or merozoite proteins,
thus indicating that the recognized antigens are expressed
in different live forms of the parasite (Table 1).
Identification of scFv antibodies that inhibit invasion of 
Eimeria tenella
To identify scFvs that interfere with sporozoite invasion,
28 scFv variants binding to oocyst extracts were selected
for further analyses, since they demonstrated distinct
sequence variations mainly localized in the complemen-
tarity determining regions (CDR). For selection of anti-BMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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body fragments interfering with cell infection by parasite,
the sporozoite invasion assay in vitro has been chosen. The
method is based on observation that certain cultured
mammalian cells, such as Madin-Darby bovine kidney
(MDBK) epithelial cells, are susceptible to invasion by
sporozoites of E. tenella even though these cells are not
natural hosts for this parasite. Accordingly, the antibodies
specifically binding sporozoite antigens involved in cell
invasion can protect the cells from the Eimeria infection
[11] (Figure 1a). For each scFv, at least two independent
invasion inhibition assays were performed. These "activ-
ity-screens" were set up to detect any scFv with evidence of
inhibitory activity. The threshold that was defined for
inhibitory activity was a = 10% reduction of intracellular
sporozoites in both independent experiments. This
requirement was met by six out of the 28 tested scFvs
(Table 2). The scFv inhibition of sporozoite invasion was
found to be dose-dependent, as demonstrated by titration
of purified antibody fragments (Figure 1b,c).
Analyses of binding properties, antigen- and species-
specificity of parasite-neutralizing scFvs
A detailed analysis of the antigen specificity of six selected
antibody fragments with proven ability to inhibit cell
invasion of E. tenella sporozoites (AA19, AA28, AB09,
AB21, AB28 and AD10) was performed using ELISA,
Western blot analysis, flow cytometry and indirect fluores-
cent antibody test (IFAT). For this purpose, the complex
antigens were prepared from different live forms of the E.
tenella parasites. In addition, a number of known most
probable antigen candidates, such as immunodominant
surface antigen EtSAG1 (TA4) [12]; microneme proteins
Table 1: Antibody variants selected by screening of an anti-Eimeria scFv library using complex antigens from E. tenella.
scFv 
nomenclature
Antigen used for 
screening
Number of 
selected clones
Number of 
unique clones
Unique clones showing cross-reactivity with the 
antigen
Oocyst extract Sporozoite 
extract
Merozoite 
extract
AA Oocyst extract 112 37 37 23 0
AB Sporozoite extract 64 35 15 35 n.t.
AC Oocyst and 
sporozoite 
membrane proteins
39 3 0 n.t. 0
AD, AE, AF Merozoite extract 67 22 3 n.t. 22
n.t., not tested.
Table 2: Invasion inhibition activity and antigen specificity of the selected scFvs.
scFv Inhibition of 
invasion (%)1
Binding to complex antigens2 Putative mol. weight of recognized 
antigen (kDa)3
Sporozoite surface binding4
Oocyst
extract
Sporozoite
extract
Merozoite
extract
Reduced Non-reduced FACS IFAT
AA19 28 ± 14 + - - 83-175 83-175 - -
AA28 36 ± 16 + - - 100-150 100-150 - -
AB09 52 ± 15 + + - n.d. 15-20 + +
AB21 32 ± 7 + + - n.d. 15-20 + +
AB28 25 ± 3 + + - Negative 15-20 + +
AD10 36 ± 12 + + - Negative 15-20 + +
1 In each experiment, 10 μg bacterially expressed and purified scFv was used. Means and SDs of triplicates are shown.
2 As determined by ELISA.
3 As estimated by comparison with molecular weight markers in Western blot analyses.
4 As determined by IFAT and flow cytometry (FACS).
+, binding; -, no binding; n.d., not determined.BMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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Inhibition of sporozoite invasion in vitro by anti-Eimeria scFvs Figure 1
Inhibition of sporozoite invasion in vitro by anti-Eimeria scFvs. (a) Analyses of Eimeria-infected cells by flow cytometry. 
Left panel, no infection; middle panel, infected cells (negative control); right panel, infection with sporozoites preincubated with 
inhibitory scFv AB28 at a concentration of 5.2 μM. In this example, 78% inhibition was observed. (b) Comparison of the inhib-
itory activity of scFvs AA19 and AB28. (c) Dose-dependent inhibition of sporozoite invasion in vitro by scFv AB28. (d) Compar-
ison of anti-sporozoite activity in vitro of scFv fragments (10 μg) produced in bacteria or in tobacco leaves. Control, buffer 
alone.
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EtMic1 [13], EtMic2 [14], EtMic3 [11] and EtMic5 [15];
Eimepsin (aspartyl proteinase) [16]; merozoite antigen
MZP 5-7 [17] and a 19 kDa antigen 3-1E (potential immu-
nostimulator) [18] were generated and expressed as
recombinant proteins. Since the EtSAG1 antigen as iso-
lated from the parasite is composed of a 17 kDa polypep-
tide (large subunit) and a 8 kDa polypeptide (small
subunit) linked by a disulfide bridge [12], recombinant
EtSAG1 protein was produced in bacteria as a 25 kDa pre-
cursor without a signal peptide and a glycosylphosphati-
dylinositol (GPI) anchor. The results of analyses are
summarized in Tables 2 and 3. Out of six tested, four scFv
candidates (AB09, AB21, AB28 and AD10) demonstrated
clear staining of the surface of E. tenella sporozoites (Table
2; Figure 2). Moreover, these four variants showed specific
binding to the recombinant EtSAG1 precursor (Table 3;
Figure 3a). SDS-PAGE and Western blot analyses revealed
that all EtSAG1-specific scFvs (AB09, AB21, AB28 and
AD10) recognized the large 17 kDa subunit of EtSAG1 in
oocyst and sporozoite extracts of E. tenella under non-
reducing conditions (Table 2; Figure 3a). In contrast, no
antibody binding was detected when the oocyst extract
was reduced (Table 2; Figure 3a). Interestingly, the
EtSAG1-specific scFvs retained binding to the 25 kDa pre-
cursor also under reducing conditions.
For analysis of cross-reactivity of the scFv fragments
selected for inhibition of invasion of E. tenella sporo-
zoites with other Eimeria species, the complex soluble
antigens were prepared from sporulated oocysts of three
avian Eimeria species (E. tenella, E. acervulina and E. bru-
netti) and two rodent Eimeria species (E. nieschulzi and E.
papillata). As expected, all EtSAG1-specific scFvs showed
reactivity only with E. tenella (Table 3). The scFv variants
AB09, AB21, AB28 and AD10 did not interact with the
protein preparations from other species, thus indicating
that they recognize EtSAG1 epitopes which are unique for
E. tenella. In contrast, the scFvs AA19 and AA28 demon-
Table 3: Antigen and species specificity of the selected scFvs with anti-sporozoite invasion activity, as determined by ELISA (E) and 
Western blot analyses (W).
scFv Recombinant antigen
EtSAG1 EtMic1 EtMic2 EtMic3 EtMic5 Eimepsin MZP 5-7 19 kDa Ag
AA19 -(E) -(W) -(E) -(W) -(W) -(W) -(E) -(E)
AA28 -(E) -(W) -(E) -(W) -(W) -(W) -(E) -(E)
AB09 +(E, W) -(W) -(E) -(W) -(W) -(W) -(E) -(E)
AB21 +(E) n.t. -(E) n.t. n.t. n.t. -(E) -(E)
AB28 +(E, W) -(W) -(E) -(W) -(W) -(W) -(E) -(E)
AD10 +(E, W) n.t. n.t. n.t. n.t. n.t. n.t. -(E)
scFv Eimeria species
E. tenella E. acervulina E. brunetti E. papillata E. nieschulzi
AA19 +(E, W) +(E, W) +(E) +(E) -(E)
AA28 +(E, W) +(E, W) +(E, W) +(E) -(E)
AB09 +(E, W) -(E, W) -(E) -(E) -(E)
AB21 +(E, W) -(E, W) -(E) -(E) -(E)
AB28 +(E, W) -(E, W) -(E, W) -(E) -(E)
AD10 +(E, W) -(E, W) -(E) -(E) -(E)
+, binding; -, no binding; n.t., not tested.BMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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strated fairly broad species cross-reactivity (Table 3; Figure
3b). However, these variants neither bound to sporozoite
and merozoite extracts nor interacted with the surface of
sporozoites (Table 2).
Oral application of tobacco expressed antibody fragments 
in chickens infected with Eimeria
Oral application of antibodies for prevention of Eimeria
infections in poultry would only be feasible if cheap
sources of large amounts of recombinant protein were
available. Production in plants provides an economically
attractive source of recombinant antibodies [19]. There-
fore, the recombinant anti-Eimeria  antibody fragments
were first expressed in leaves of the tobacco plant Nico-
tiana benthamiana as a quick source of large amounts of
plant-made recombinant protein. Typically, one-step
purification yielded 20, 100, 90, 400 and 60 mg of recom-
binant scFv variants AA28, AB09, AB21, AB28 and AD10,
respectively, with purity above 90% from 1 kg wet weight
of infiltrated tobacco leaves (Figure 4). Comparison of the
anti-sporozoite activity in vitro of the antibody fragments
isolated either from tobacco or from E. coli demonstrated
superior properties of the plant-produced material for
most of the tested anti-Eimeria scFvs (Figure 1d).
Animal studies were performed to assess whether the scFv-
mediated inhibition of sporozoite invasion observed in
vitro also prevents or mitigates Eimeria infections in chick-
ens upon oral delivery of the scFvs. For these experiments,
we used purified antibody fragments produced and iso-
lated from the tobacco leaves. The chickens were orally
infected with a single dose of E. tenella oocysts (500
oocysts per bird). One day before infection, force-feeding
was started with the scFv fragments and continued for 9
days. Birds in the treatment group received 1 mg antibody
isolated from the tobacco leaves in 1 ml PBS a day via gav-
age. The results of two independent animal trials per-
formed in the same way are summarized in Figure 5. The
untreated control groups showed oocyst shedding starting
on day 6 after challenge and increasing throughout day 7.
At the same time points, treatment with the commercial
anti-coccidian drug Baycox® reduced oocyst shedding to
marginal levels. Animals that received scFvs experienced a
partial (35-60%) reduction in oocyst numbers in compar-
ison with the untreated controls; however, there was no
significant difference. The individual data sets of scFv-fed
groups showed a fairly high variability between the exper-
iments. Nevertheless, all tested scFv variants demon-
strated a somewhat positive effect on oocyst shedding
with the highest inhibition rate of 60% observed for the
group treated with a scFv AD10.
Pea plant transformation and expression of scFvs in pea 
seeds
Although the transient expression of heterologous pro-
teins in leaves of N. benthamiana allows relatively quick
production of reasonable quantities of the scFv fragments
for proof-of-concept (POC) animal studies, application of
antibodies as fodder additives in routine poultry feeding
requires more efficient and cost-effective production sys-
tems. Therefore, stable expression of single-chain anti-
body fragments was established in the fodder pea variety
"Eiffel". For generation of the transgenic pea lines, the
genes of scFv fragments of two different specificities (anti-
EtSAG1 scFv AB28 specific for E. tenella and scFv AA28
with the broadest cross-reactivity to Eimeria species) were
selected. The transgenic pea lines have been generated
which express scFvs under the control of a seed-specific
promoter. The results of characterization of AB28-express-
ing pea lines are summarized in Additional files 1, 2, 3 &4.
IFAT analysis demonstrating specific binding of scFv AB28 to  sporozoites of E. tenella (a) and lack of interaction with spo- rozoites of E. acervulina (b) and E. brunetti (d) Figure 2
IFAT analysis demonstrating specific binding of scFv 
AB28 to sporozoites of E. tenella (a) and lack of inter-
action with sporozoites of E. acervulina (b) and E. bru-
netti (d). Negative control (binding of irrelevant scFv) is 
shown in panel (c). Blue fluorescence (DAPI), staining of 
nuclei; red fluorescence (Evans blue), staining of sporozoite 
refractile bodies and cytoplasm; green fluorescence (FITC), 
specific antibody staining. In panel (e), a fluorescence micros-
copy image is shown of intracellular sporozoite in infected 
HepG2 cell. Staining was performed with scFv AB28 followed 
by anti-c-myc MAb and Alexa488-conjugated anti-mouse anti-
body.
(a)
(c)
(b)
(d)
(e)BMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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Similar analyses were performed for the AA28-transgenic
pea lines. The tests demonstrated that scFv expression was
restricted to seeds, where the scFv protein could unambig-
uously be detected by Western blot analysis (Additional
file 1). For estimation of the expression levels, the scFv
antibody fragments were isolated from the pea seeds and
purified. Three independent measurements yielded 1.76 ±
0.41 mg extractable functional scFv AB28 per 1 g dry seed
weight. Furthermore, the scFv expression levels stayed the
same over a number of following homozygous pea gener-
ations (1.66, 1.92, 1.64 and 1.90 mg scFv per 1 g dry seeds
of generations F4, F5, F6 and F7, respectively). Head-to-
head comparison of scFv AB28 preparations isolated
either from the tobacco leaves (n = 5) or from the pea
seeds (n = 3) demonstrated nearly identical molecular
form compositions in different preparations. The scFv
material from both tobacco leaves and pea seeds was
mostly monomeric (73.10 ± 6.27% and 76.65 ± 13.22%
for the tobacco and pea material, respectively) with pres-
ence of a dimeric (diabody [20]) fraction (25.68 ± 6.08%
and 20.80 ± 9.62%, for the tobacco and pea material,
respectively) and some minor quantities of higher molec-
ular forms, most probably tetramers (1.17 ± 0.44% and
2.5 ± 0.35%, for the tobacco and pea material, respec-
tively) (Figure 4d and Additional file 5). Accordingly, the
scFv preparations from the tobacco leaves and pea seeds
demonstrated very close similarity (P = 0.192) in their
antigen-binding activities, with the calculated KD values of
3.53 ± 1.24 nM (n = 3) and 2.60 ± 0.73 nM (n = 5), respec-
tively, as determined by ELISA (Additional file 5).
Analysis of the proteolytic and pH stability in vitro
For an effective prevention of parasite invasion into the
intestinal epithelium of chickens, the antibody fragments
must survive the harsh conditions of the GI tract, in par-
ticular, high protease content and acidic pH, for a longer
time. It is known that avians possess the same basic struc-
tures for nutrient extraction as other vertebrates but also
exhibit specific features within their GI tract. These
include a crop for storage of feed, a proventriculus (simple
stomach), a gizzard and paired caeca. The pH values of
specific sections of the chicken GI tract are the following:
crop 4.5, proventriculus 4.4, gizzard 2.6, duodenum 5.7
to 6.0, jejunum 5.8, ileum 6.3, colon 6.3, caeca 5.7, and
bile 5.9 [21]. We, therefore, performed comparative anal-
yses of influence of the expression system on the pH and
proteolytic stability of the antibody fragments using as an
example the EtSAG1-specific scFv AB28. First, we tested
the influence of different pH conditions separately on for-
mation of the antibody-antigen complexes ("binding") as
well as on dissociation of already preformed antigen-anti-
body contacts ("dissociation"). The purified scFv AB28
preparations isolated either from tobacco leaves or from
the transgenic pea seeds were compared. In addition,
crude protein extract prepared from AB28-expressing pea
seeds was included into the assay. The results presented in
Figure 6a,b demonstrate a fairly comparable effect of pH
on all three antibody preparations. As expected from the
general considerations, the marginal pH values had a
more pronounced negative effect on the formation of the
antigen-antibody complexes than on dissociation of the
already bound antibody. In general, the found pH effect
on formation and dissociation of the antibody (Ab)/anti-
gen (Ag) complexes rather reflects the stability of the Ab/
Ag interface partly formed by the electrostatic interactions
and hydrogen bonds between the charged and polar
amino acid side chains than the folding/unfolding stabil-
ity of the antibody molecules themselves. In conclusion,
Analyses of specificity of sporozoite-neutralizing scFvs Figure 3
Analyses of specificity of sporozoite-neutralizing 
scFvs. (a) Western blot analysis of antigen specificity of scFv 
AB28. Lanes: M, molecular mass markers (values in kDa are 
shown on the left); 1,2, produced in E. coli 25 kDa precursor 
of a GPI-anchored surface antigen EtSAG1 under reducing 
and non-reducing conditions, respectively; 3,4, oocyst 
extract of E. tenella under non-reducing and reducing condi-
tions, respectively. (b) Species specificity of scFv AA28, as 
determined by ELISA using oocyst extracts from three avian 
(E. tenella, E. acervulina, E. brunetti) and two rodent (E. papil-
lata and E. nieschulzi) Eimeria species. As a negative control, 
secondary anti-c-myc tag antibody followed by HRP-conju-
gated goat anti-mouse IgG antibody was used.
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all tested scFv AB28 preparations retained 70-100% of
their maximal antigen-binding activity under the pH con-
ditions prevalent in the caeca where the E. tenella sporo-
zoite invasion takes place [22].
To simulate the protease-rich conditions of the small
intestine, activity and stability of different scFv AB28 prep-
arations were tested in presence of enteric proteases
present in the intestinal fluid (chyme) isolated from the
small intestine of chickens. Comparison of purified scFv
AB28 preparations isolated either from the tobacco leaves
or from the pea seeds demonstrated a three-fold higher
resistance of pea-expressed material against proteolytic
degradation in the small intestine (Figure 6c; Table 4). The
scFv material present in crude pea seed extract appeared
even more stable, 40-fold more resistant than scFv puri-
fied from pea seeds and 100-fold more stable than scFv
from tobacco. This finding indicates a protective anti-pro-
tease effect of the pea seed content. To analyze whether
this protective effect is seed-specific or just caused by the
high protein content of the pea flour, we compared prote-
olytic stability of the tobacco-produced scFv AB28 in the
presence of either wild-type (wt) pea seed extract or irrel-
evant protein, such as bovine serum albumin (BSA). The
final BSA concentration was 15% (w/v), as adjusted
according to the measured protein content of the pea seed
extract. The results presented in Figure 6d and Table 4
indicate that presence of excess of irrelevant protein had
no effect on scFv degradation in chicken intestinal fluid
and that the stabilizing effect could be attributed exclu-
sively to the content of the pea seed extract (45-fold gain
in stability). The tobacco-made scFv AB28 premixed with
the wt pea seed extract proved nearly as stable as an extract
prepared from the AB28-expressing transgenic pea seeds
(Figure 6d).
Reduction of parasite shedding upon force-feeding of 
chickens with pea seed flour prepared from scFv-
expressing seeds
To test whether pea seeds expressing protective scFvs can
avert infection with E. tenella, the flour prepared from the
AB28-expressing seeds was used for treatment of chickens
infected with E. tenella oocysts. For comparison, expressed
in tobacco and purified scFv AB28 and an irrelevant scFv
BA11 raised against enterotoxigenic Escherichia coli
(ETEC) as well as BA11-containing pea seed flour were
used. The study was designed to mimic the normal hous-
ing conditions, such as keeping birds in clean stables
where only a few oocysts could be present which survived
the disinfection procedure. A preliminary dose finding
study demonstrated that infection with a dose as low as 7-
15 oocysts per chicken results in measurable oocyst shed-
ding. In addition, lowering the infection dosages led to a
significant reduction of deviation between the individual
animals. Therefore, the animals were infected with manu-
ally prepared individual doses of 20 ± 1 oocysts. The
chickens were force-fed three times daily either with 1 mg
in total of scFvs purified from the tobacco leaves or with
the flour prepared from the scFv-expressing pea seeds. In
latter case, the maximal delivered dose of functional scFv
was estimated to be 0.5 mg per bird a day (see Methods).
The results of the study are shown in Figure 7a. The aver-
age oocyst shedding was 1.5-fold lower in birds treated
with the expressed in tobacco and purified scFv against
Eimeria (AB28) in comparison to birds that were treated
with the same amount of a purified irrelevant scFv
(BA11), although the difference was not significant (P =
0.116). However, treatment with AB28-containing pea
seed flour resulted in a significant 2.5-fold lower average
oocyst shedding than in the animal group receiving BA11
pea flour (P = 0.033). For groups treated with the pea
material, the anti-Eimeria scFv antibody AB28 showed an
infection inhibition of 60.5%. For groups treated with the
purified material, essentially lower inhibition (34.7%)
was observed.
Mitigation of Eimeria tenella infection by application of 
scFv-containing pea seeds in chicken feed
For demonstration of the potential of fodder containing
AB28-pea shred in prevention or mitigation of the coccid-
ian infection caused by E. tenella, the controlled battery
experiments were performed under normal ad libitum
feeding conditions. To determine whether the transgenic
pea shred is accepted as a part of the feed and readily taken
up by chickens as well as to assess the digestibility of the
pea shred, a preliminary feeding study was performed
using a fodder containing 10% pea shred derived from the
pea seeds expressing irrelevant anti-ETEC scFv antibody
BA11. The results shown in Additional file 6 demon-
strated no difference in weight gain and feed consump-
tion between the BA11-fed chickens and the animals of
the control group. The transgenic pea shred was well con-
sumed by broiler chickens and was not shunned (Addi-
tional file 6). ELISA analyses demonstrated absence of the
BA11-activity in extracts from the fecal material, thus indi-
cating that the recombinant antibody present in trans-
genic pea seeds was completely digested (data not
shown).
In our feasibility studies, we evaluated high- and low-dose
infection models. The high dose model was designed to
get appropriate lesion scores for differentiation of infec-
tions. However, taking into account that the lesion score
analysis is not always a reliable method to measure the
efficacy of anti-coccidials [23], the reduction of oocyst
counts in caeca was determined as an endpoint of the
study. Broiler chickens were infected orally with individ-
ual doses of 2,500 freshly prepared oocysts of E. tenella.
Three animal cohorts were formed; in two groups birdsBMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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were infected and fed with the fodder comprising 10%
pea shred derived either from AB28-expressing seeds
(treatment group) or from the wild-type pea (positive
control of infection). Adapted from the preliminary feed-
ing experiment, the average consumption of the scFv anti-
body by chickens of the treatment group was estimated as
35.63 ± 1.87 mg antibody/kg body weight × day (Addi-
tional file 7). The negative control group (control of spon-
taneous infection) comprised birds which were not
infected and received conventional fodder. At the end of
experiment, the lesion scores and the oocyst counts were
determined in caeca of sacrificed birds. The results of the
study demonstrated that there was no significant differ-
ence in the body weight gains (P = 0.068) and severity of
Analysis of scFv AB28 expression in tobacco leaves Figure 4
Analysis of scFv AB28 expression in tobacco leaves. (a, b) Reducing 12% SDS-PAGE analysis of leaf discs: Coomassie 
staining (a) and Western blot with detection using anti-His antibody (b). Lanes: M, molecular mass markers (values in kDa are 
shown on the left); 1-5, leaf materials after expression of scFv AB09, AB28, AD10, AA28 and AB21, respectively; 6,7, negative 
controls (tobacco expressing GFP and wt plants, respectively). (c,d) Characterization of tobacco expressed scFv AB28 after 
purification. (c) Coomassie stained 12% SDS-PAA gel. Lanes: M, molecular mass markers; 1-4, scFv samples (1.3, 2.6, 5.2 and 
13 μg, respectively). (d) Analysis of scFv AB28 molecular forms by size-exclusion FPLC on a calibrated Superdex 200 column. 
The positions of the molecular weight markers are indicated.
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the lesions (P = 0.205) between the infected groups. How-
ever, less animals in the AB28-treated group had blood in
feces (40% vs. 44% in the positive control group) and a
higher proportion of the AB28-treated animals had light-
weight lesions (50% AB28-pea fed animals had lesion
scores 0 and 1 vs. 40% in the positive control group).
Accordingly, only 26% of the AB-28 treated animal had
lesion score 3 versus 36% in the positive control group.
Although the mentioned differences were not statistically
significant, the observed trend was confirmed when the
oocyst counts from caeca were compared (Figure 7b). The
average oocyst counts were significantly lower in birds fed
with the AB28-expressing pea seeds than in animals
receiving conventional fodder (P = 0.038). Feeding with
AB28-pea led to reduction of the oocyst counts in caeca to
65.9% of the numbers found in the positive control
group. Therefore, the inhibition of invasion caused by the
AB28-transgenic fodder could be calculated as 34.1%.
The low-dose infection model was employed to mimic the
real situation in barns for rearing commercial broilers
where the chickens are spontaneously infected with rela-
tively low dosages of Eimeria oocysts. The feeding experi-
ment was performed under nearly the same conditions as
the high-dose infection experiment, only the infection
dose has changed. In this study, the chickens were infected
with the ten-fold lower oocyst doses, i.e. 250 oocysts per
bird. Due to the low oocyst doses, the vast majority of
infected chickens had reduced lesion scores 0 and 1
(100% and 96% in AB28-treated and in positive control
groups, respectively). The animal cohort fed with AB28-
pea seeds demonstrated significantly lower oocyst counts
in caeca (P = 0.032). However, about one third of animals
in both infected groups stayed oocyst-free most probably
due to the innate immunity against the pathogen. There-
fore, the effect of modified feed was also separately
assessed only for the oocyst-shedders in each group. The
results presented in Figure 7c demonstrate very significant
reduction of caecal oocyst counts in the birds fed with the
AB28-containing fodder (P = 0.002). In summary, feeding
with AB28-pea seeds led to a reduction of the oocyst
counts in caeca to a level of 29.2% from the counts found
in the positive control group. Therefore, the inhibition of
invasion caused by the scFv AB28 pea seed material could
be calculated as 70.8%.
Discussion
In view of the spread of microbial resistance to antibiotics
and the emergence of new pathogens, passive immuniza-
tion by recombinant antibodies is considered as one of
the most promising alternatives to combat infectious dis-
eases [24,25]. Although the market for therapeutic mono-
clonal antibody-based products is one of the fastest
growing segments in the biopharmaceuticals industry,
this market is heavily focused on oncology, autoimmune
and inflammatory diseases. The role of antibodies for mit-
igation and therapy of infections is only slowly emerging,
but is impeded by the high Cost of Goods (COG). High
COG also prevents successful introduction of antibodies
into the animal health market. Plant-based production
provides a solution to these cost problems. In addition,
plants can provide an adequate system for oral delivery of
recombinant biomolecules as part of the diet. Infrastruc-
ture and costs for downstream processing can thus be
avoided, as well as the production losses which are often
significant. Although expression of recombinant antibod-
ies and antibody fragments in plants ("plantibodies") has
been demonstrated two decades ago [26], their introduc-
tion into the health and veterinary markets is still years
away. In our knowledge, the present report is a first dem-
onstration of feasibility to control poultry infections by
feeding animals using a fodder supplemented with the
antibody producing transgenic seeds.
The first objective of this study was generation of recom-
binant neutralizing antibodies against the economically
important protozoan parasites of genus Eimeria. An
immune library was constructed by phage display and
panned against the complex antigens prepared from the
different live forms of E. tenella. Since the orally delivered
antibodies cannot rely on effector functions of circulating
immunoglobulins such as Fc-receptor mediated recruit-
ment of the immune killer cells (ADCC) or complement
fixation (CDC) inside the GI tract, the only possible
mechanism of action would be prevention of the parasite
Evaluation of activity in vivo of orally applied anti-Eimeria anti- bodies Figure 5
Evaluation of activity in vivo of orally applied anti-
Eimeria antibodies. Infection outcomes were assessed by 
quantifying the amounts of Eimeria oocysts in feces of the 
infected chickens. Birds in the treatment groups received 1 
mg antibody isolated from tobacco leaves in 1 ml PBS a day 
via gavage. The negative treatment group received buffer 
alone. Animals of the positive control group received 1 ml of 
a 2.5% solution of the anti-coccidial drug Baycox® (Bayer 
HealthCare) in water. The results of two independent stud-
ies are presented. Mean values and SDs for each treatment 
group are plotted. The numbers of animals in each chicken 
cohort are indicated on the bars.
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entry into the gut epithelium. Therefore in contrast to the
previously described approaches [27,28], we introduced
screening of binders for the parasite neutralizing activity
early into the selection process. This strategy resulted in
identification of six candidates; four of them appeared to
be specific for EtSAG1 (TA4) sporozoite antigen of E. ten-
ella. EtSAG1 has been found previously by us and others
to be a molecular target for a number of sporozoite-neu-
tralizing antibodies [12,29,30] and seems to be closely
involved into initiation of the infection process [30]. The
antigen specificities of two neutralizing non-EtSAG1
binders and the mechanism of their infection-blocking
activity are still unknown, since both these variants bound
neither sporozoites nor merozoites.
The second goal of the study was testing the suitability of
orally applied antibody molecules for controlling the
Eimeria infection. To make the product compatible with
the already existing cost structures in the animal health
market, the cost efficient plant production systems have
been utilized. First, the selected antibody fragments were
transiently expressed in agrobacteria-infiltrated tobacco
leaves and purified. Besides the higher production yields,
the tobacco-derived antibody fragments demonstrated
superior biological activity in vitro in comparison with the
counterparts expressed and purified from bacteria. Fur-
thermore, the relatively small quantities of tobacco-made
scFv fragments (1 mg per chicken a day, 8 day treatment)
Analyses of pH and proteolytic stability of scFv AB28 preparations purified either from tobacco leaves or pea seeds and of the  AB28-containing pea seed extract Figure 6
Analyses of pH and proteolytic stability of scFv AB28 preparations purified either from tobacco leaves or pea 
seeds and of the AB28-containing pea seed extract. (a, b) pH influence on formation ("binding") and disruption ("disso-
ciation") of the antibody-antigen complexes formed by different AB28-preparations (a and b, respectively). (c, d) Loss of anti-
gen-binding activity of scFv AB28 preparations as a result of degradation by intestinal proteases. (c) Comparison of purified 
scFv AB28 isolated either from tobacco leaves or from pea seeds as well as of crude protein extract from the scFv-expressing 
seeds (seed extract). (d) Effect of irrelevant protein (BSA) or wt pea seed extract on proteolytic stability of scFv AB28 
(tobacco) in chicken intestinal fluid. For comparison, a degradation curve for AB28-transgenic seed extract is shown. The 
residual antigen-binding activity was determined by ELISA using the plates coated with the oocyst extract of E. tenella and plot-
ted against the chicken intestinal fluid dilutions.
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were able to cause partial reduction of Eimeria  oocyst
shedding by the infected animals.
Although the transient and stable expression in tobacco
leaves allows the cost-reasonable industry-scale produc-
tion of heterologous proteins [31,32], it requires fairly
intense product purification strategies, to remove at least
the toxic alkaloids from the tobacco extracts. In contrast,
expression of the therapeutic proteins in crop seeds has a
great advantage for oral administration since only mini-
mal treatment is necessary to use seeds as the livestock
fodder. The other advantages of crop plants include easy
upscaling through field cultivation, established harvesting
and processing technologies, as well as easy seed storage
and distribution. Seeds are natural storage organs, with
the optimal biochemical environment for the accumula-
tion of large protein amounts. In this form, proteins can
be transported from farm to the production factories with-
out any loss of stability. Moreover, feasibility of high-level
production and long-term storage of antibodies in seeds
has already been demonstrated [33,34]. In our work, we
have selected feed pea as a production plant on the basis
of the following considerations. Pea is an established field
crop with available infrastructure and tools for large scale
planting, weeding, harvesting, storage and processing.
Furthermore, the pea seeds are an established feed/food
ingredient with high protein content (up to 40% [35]).
Pea has a history of successful heterologous expression
studies including field trials (own unpublished data) and
has excellent safety features. The safety aspects include
strict self-pollination; lack of outcrossing; no dispersal of
seeds by wind and, therefore, very low number of volun-
teers; lack of toxic substances in seeds. The eaten seeds get
digested and thus are not able to germinate; the pea plants
do not survive frost. In addition, the pea varieties are
approved as crop plants for livestock fodder. Due to the
different sugar and glycopeptides contents, the feed pea
has different taste and texture than the food pea, thus
allowing easy discrimination to prevent potential entering
of GMO into the food chain. In addition, using seed-spe-
cific promoter makes expression of the transgenic protein
nearly totally restricted to the seeds [36]. The safety fea-
tures are very important in view of tight regulatory control
and surveillance of genetically modified (GM) plants [37].
We have, therefore, generated transgenic pea plants
expressing two most promising scFv candidates in seeds.
The highest producer, a homozygous pea line expressing
anti-EtSAG1 scFv AB28 at yields of 1.5-2 g extractable
functional antibody per 1 kg dry seeds, was taken for the
detailed analyses and feasibility studies in animals. Com-
parison of the scFv fragments isolated from the pea seeds
with the counterparts expressed in tobacco leaves (a plant
expression system most often used for production of anti-
bodies and their fragments [31,34]) demonstrated no dif-
ference in the molecular form composition, antigen
binding activity and pH stability, but a somewhat higher
resistance of the pea seed derived material against intesti-
nal proteases. Comparative analysis of the proteolytic
resistance revealed a key protective role of the pea seed
extract in scFv stability. The stabilizing effect can be attrib-
uted to the well-known presence of the proteinase inhibi-
tors in legume seeds [38]. The trypsin/chymotrypsin
inhibitors found in pea seeds mainly belong to the Bow-
man-Birk protease inhibitor (BBI) family. BBIs are stable
at cooking temperatures and also towards acidic pH val-
ues in the digestive systems of humans and animals, most
probably due to their large number of disulfide bonds
(seven bonds out of about 70 amino acid residues) and
the polar interactions between the sub-domains. The
potential applications of BBIs have recently attracted
much attention. BBIs are already used to defend against
insects in transgenic plants, and they also have prospects
in the prevention of cancer, Dengue fever, and inflamma-
tory and allergic disorders (for review see [39,40]). These
findings provide an additional argument for choosing the
legume seeds as the production system suitable for passive
immunization.
The controlled feeding experiments demonstrated statisti-
cally significant positive effect of using antibody-express-
ing transgenic pea seeds on mitigation of coccidial
infection. In first instance, force-feeding with the pea flour
suspension appeared to be more efficient than the oral
administration of twice larger amounts of purified anti-
body fragments. The found effect was additionally con-
firmed by ad libitum feeding using both high- and low-
dose infection models. The challenge doses of E. tenella
oocysts that were used in the first model (2.5 × 103) may
be considerably greater than the levels that commercial
birds are likely to be exposed to in some production facil-
ities. Nevertheless, the observed endpoint of the study
(reduction of oocyst counts is caeca) was still significant.
Much better results were obtained by using the ten-fold
lower challenge oocyst doses. Therefore, the transgenic
pea seeds may be useful for protection against coccidiosis
Table 4: Effect of expression system and additives on proteolytic 
stability of scFv AB28.
scFv preparation ED50
scFv (tobacco) 3,786.00
scFv (pea) 1,209.00
scFv (tobacco) + 15% BSA 3,053.00
scFv (tobacco) + wt pea seed extract 83.24
AB28-pea seed extract 33.47
ED50, effective dilution of chicken intestinal fluid leading to 50% loss of 
activity.BMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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Evaluation of anti-Eimeria activity in vivo of fodder containing antibody-expressing pea seed flour or shred Figure 7
Evaluation of anti-Eimeria activity in vivo of fodder containing antibody-expressing pea seed flour or shred. (a) 
Analysis of activity in vivo of orally applied antibody-containing pea seed flour (force-feeding). The animals were infected with 
manually prepared individual doses of 20 ± 1 oocysts. Two evaluation groups (n = 11) were treated with the material contain-
ing anti-Eimeria scFv AB28, one group received pea flour from seeds expressing AB28 and the other group was treated with 
the antibody fragment isolated from the tobacco leaves. As positive controls of infection, two animal groups (11 birds in each) 
were treated with the same quantities of material comprising the irrelevant BA11 antibody, either in form of pea flour or as 
soluble antibody isolated from the tobacco leaves. The negative control group comprised five birds to who heat inactivated 
oocysts were given. The oocyst counts were determined in individual feces and each sample was counted six times by two dif-
ferent persons. The infection outcomes were assessed by quantifying the amount of Eimeria oocysts in feces of infected chick-
ens at days 7 and 8 p.i. (days of maximal oocyst release). (b) High infection dose model (ad libitum feeding). Three treatment 
cohorts were evaluated: group 1 (n = 30) received fodder with 10% AB28-pea shred; group 2 (n = 25), positive control for 
infection (infected, not treated); group 3 (n = 5), negative control of infection (non-infected, not treated). The birds in groups 
2 and 3 were fed with the fodder containing 10% wt pea. Infection outcomes were assessed by quantifying the amounts of the 
Eimeria oocysts in caeca of infected chickens at day 7 p.i. (c) Low infection dose model (ad libitum feeding). Infection outcomes 
were assessed by quantifying the amounts of the Eimeria oocysts in caeca of infected chickens at day 7 p.i. Due to the relatively 
low infection rate, only the oocyst shedding animals were considered, i.e. 17 birds from the group 1 (AB28) and 13 animals 
from the group 2.
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in poultry raised under normal field conditions, as we
demonstrated using the low-dose infection model.
Although the results presented here are rather prelimi-
nary, they provide evidence that the recombinant anti-
bodies produced in pea seeds have capacity to reduce the
infectious loads in animals following oral administration.
Product-specific issues such as antibody stability in the
gut, parasite neutralizing potency or even direct killing
activity have to be addressed, as well as technical issues
(increasing the production yields and shortening time for
GM plant generation) and commercial applicability. For
example, in the present study we used the scFv variants
selected from the phage display immune library without
any further optimization. Affinity maturation of the scFv
candidates and improving their proteolytic stability and
folding efficacy in plants using either random or rational
approaches [41] may further contribute to the success of
the described passive vaccination strategy. The antibody
stability against intestinal proteases can also be enhanced
by conversion of scFv into a bivalent single-chain anti-
body format without compromising the expression yields
in plants that is normally observed for heterooligomeric
full-length antibodies of IgG and IgA classes or Fab frag-
ments (Giersberg et al., manuscript in preparation). Alter-
natively, well expressed and proteolytically stable binding
proteins selected from the non-antibody scaffold libraries
can be used (for review see [42]). In addition, further
enhancement of anti-parasite potency can be achieved, for
example, by grafting the killing antimicrobial peptides
into the antibody CDR loops not involved into the anti-
gen binding [43].
Conclusion
Taken together, this study demonstrated for the first time
beneficial effect of using antibody expressing pea seeds for
passive protection against avian coccidiosis in newly
hatched birds. Compared with methods of active vaccina-
tion either by live parasites (wild-type and/or attenuated
strains) or using recombinant subunit or DNA vaccines
[1], the passive immunization strategy described here is
an easy and non-invasive method to use in commercial
settings with the comparatively low cost of production
utilizing current agriculture technologies and with the
ability to be used in combination with other anti-parasitic
agents.
Methods
Immunization of mice and generation of a phage display 
antibody library
For library generation, six BALB/c mice were immunized
by injecting 100 μl of a mixture containing 1.0 to 3.9 × 106
purified parasites (oocysts, sporocysts and sporozoites) of
five Eimeria strains (E. tenella, E. acervulina, E. necatrix, E.
maxima and E. brunetti). For immunization, the Eimeria
oocysts were sporulated and used for isolation of viable
sporozoites as described by Raether et al. [44]. The protein
extracts from sporulated oocysts and sporozoites were
prepared by vortexing the parasite stages with glass beads
in PBS containing 1 mM PMSF, followed by six freeze-
thaw cycles for parasite disruption and sonication on ice.
Soluble extracts were obtained by additional centrifuga-
tion for 10 min at 13,000 g. Three immunizations were
applied on day 1, day 21 and day 41, respectively. Success-
ful immunization was monitored by performing IFAT
tests with immobilized E. tenella sporozoites. RNA was
isolated from spleens of the mice (RNAeasy Midi-Kit, Qia-
gen) and polyA+ RNA purified (Oligotex-mRNA-Mini-Kit,
Qiagen). First strand cDNA was obtained using the Super-
Script First-Strand Synthesis System for RT-PCR from
Gibco BRL. PCR amplification of the VH and VL regions
using minimal primers Bi3f/Bi4 for VH and Bi5c/Bi8b for
VL [45] was used as quality-control for the cDNA. For the
construction of the phage-display library, cDNA encoding
the VH and VL domains was generated by PCR using a
described mouse immunoglobulin primer set [46]. As a
vector for phage surface display, a phagemid pEXHAM1
[47] was used which was derived from pSEX81 [48] by
inserting a DNA sequence encoding a tag that consists of
six histidine residues (His6-tag), an amber stop codon
(Am), and a c-myc epitope between the scFv and the M13
g3p gene. The amplified VH genes were cloned as NcoI-
HindIII fragments to substitute a VH gene of a dummy scFv
containing a YOL-linker [49] in the pEXHAM1 vector. The
ligated phagemids were used for transformation of E. coli
XL1-Blue cells (Stratagene) to generate a VH sublibrary of
107 individual clones. The produced DNA was used for
cloning the VL gene repertoire as MluI-NotI DNA frag-
ments. The overall achieved scFv library complexity was
5.5 × 107 individual clones.
Screening of the phage-display library and selection of 
Eimeria-specific antibodies
The antigen immobilization and library screening was
performed according to published protocols [45,46]. For
isolation of scFvs that bind to Eimeria proteins, soluble
protein extracts of E. tenella oocysts, sporozoites and
merozoites were used as complex antigens for panning of
the scFv library. Merozoites were isolated from the intesti-
nal scrapings according to Shirley [50]. The merozoite
protein extracts were prepared as described above for the
oocysts and sporozoites. The cell pellets resulting from
preparation of soluble protein extracts of oocysts and spo-
rozoites were used to extract the membrane proteins. Cell
pellets were resuspended in extraction buffer (0.1 M Tris-
HCl, pH 6.8, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF)
and incubated at 4°C overnight. The membrane protein
fraction was separated by centrifugation for 20 min at
13,000  g. For antigen immobilization, Nalge/Nunc-
microtiter plates were coated with 2 μg Eimeria extracts inBMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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PBS overnight at 4°C. After blocking with 2% BSA/PBS, 5
× 1010 cfu phages were added to the wells and incubated
at room temperature for 2 h. After repeated washing (16×
with PBS/0.1% Tween, 4× with PBS), the bound phages
were eluted with 0.1 M triethylamine, pH 12.3. The eluate
was immediately neutralized with 1 M Tris-HCl, pH 7.4
and used for infection of E. coli XL1-Blue cells in 2xYT
medium. The rescued phagemids were packaged into the
phage particles by superinfection of the phagemid-con-
taining bacteria with M13K07 helper phage in 2xYT, 2%
glucose, 100 μg/ml ampicillin followed by incubation in
presence of kanamycin (70 μg/ml) at 30°C overnight.
Phage particles were collected from the culture medium
by precipitation with 1/5 volume 20% PEG 6000/2.5 M
NaCl and used for the next round of panning. In the first
round of panning, 5 × 1010scFv phages were applied, after
three rounds of panning, amplification, and re-panning,
112 clones expressing scFv were obtained that bound the
oocyst extract, 64 clones which bound sporozoite protein,
39 clones that bound membrane proteins from oocysts
and sporozoites and 67 clones that bound merozoite pro-
teins.
Bacterial expression, isolation and purification of scFvs
The selected binders were initially produced in E. coli bac-
teria carrying the pEXHAM1 phagemids encoding the cor-
responding scFvs. Bacterial expression was performed
essentially as described [45]. Bacteria were grown at 37°C
in LB medium containing 10 mM glucose and 100 μg/ml
ampicillin until OD600 of 0.6. Expression of the recom-
binant protein was induced by adding IPTG to a final con-
centration 50 μM followed by further incubation of
bacteria at 30°C for 3 h. For isolation of periplasmic
extracts, the bacterial cells were harvested by centrifuga-
tion at 4°C and resuspended in 1/10 initial volume of
cold spheroplast buffer (20% sucrose, 50 mM Tris-HCl, 1
mM EDTA, pH 8.0). After incubation for 20 min on ice,
the spheroplasts were separated by centrifugation at 6,200
g at 4°C for 10 min. The supernatant containing the peri-
plasmic extract was collected and further cleared by addi-
tional centrifugation at 30,000 g at 4°C for 30 min. For
analyses of activity in ELISA, the periplasmic extracts were
thoroughly dialyzed against PBS (50 mM KH2PO4/
K2HPO4, 150 mM NaCl, pH 6.6). The antibody fragments
were isolated from periplasmic extracts by immobilized
metal affinity chromatography (IMAC) on Ni-NTA His-
bind resin (Novagen) according to the manufacturer's
instructions. Eluted fractions were analyzed for presence
of antibody fragments by SDS-PAGE followed by
Coomassie staining and by Western blot analysis using
either anti-His-tag or anti-c-myc antibodies for detection.
Fractions containing the target protein were pooled and
prepared for ion-exchange chromatography (IEC). The
protein solutions were dialyzed against an appropriate
low-salt loading buffer with a pH approximately 1 pH-
unit above or below the calculated isoelectric point (pI).
The following loading buffers were used for IEC: 50 mM
imidazole-HCl, pH 6.4 or pH 7.0, and 20 mM Tris·HCl,
pH 8.0, for cation-exchange chromatography on Mono S
5/50 GL column (GE Healthcare Bio-Sciences AB, Upp-
sala, Sweden) and for anion-exchange chromatography
on Mono Q 5/50 GL column (GE Healthcare), respec-
tively. Separation was carried out using Äkta FPLC (GE
Healthcare) with a linear salt gradient (0-1 M NaCl) in the
loading buffer. Elution fractions of 1 ml were collected
and analyzed by SDS-PAGE followed by Coomassie stain-
ing and by Western blot analysis, as mentioned above.
Selected fractions were pooled and thoroughly dialyzed
either against PBS for analysis of scFv activity in ELISA or
against DMEM-light (1.8 mM CaCl2 × 2H2O, 5.4 mM KCl,
0.8 mM MgSO4 × 7H2O, 110 mM NaCl, 44 mM NaHCO3,
1 mM NaH2PO4 × 2H2O, pH 7.4) for the invasion inhibi-
tion assay. The protein concentrations of purified scFv
preparations were determined according to Bradford [51]
using the Bio-Rad Protein Assay (Bio-Rad Laboratories
GmbH, Munich, Germany). If the final protein concentra-
tion was below 1 mg/ml, the preparation was further con-
centrated using Vivaspin-6 or -20 (5000 MW PES,
Sartorius AG, Göttingen, Germany). The antigen-binding
activity of scFv preparations was tested in ELISA using
oocyst extracts and/or recombinant antigens. Milk pow-
der was used as a negative control antigen. The scFv prep-
arations were stabilized by adding 1% (w/v) bovine
serum albumin (BSA), chilled in liquid nitrogen and
stored at -80°C.
In vitro invasion inhibition assay
The invasion inhibition assay is based on the observation
that Eimeria sporozoites are able to invade cultured MDBK
cells. The assays were performed essentially as previously
described [11,52]. In brief, sporozoites from cryopreserva-
tion were thawed and washed or freshly isolated sporo-
zoites of E. tenella were labeled in HBSS (Invitrogen) with
1 μM 5,6-carboxy-succinimidyl-fluoresceine-ester (CFSE,
Invitrogen) for 30-60 min and washed twice with DMEM
medium supplemented with 2.5% FCS (Invitrogen
GmbH, Karlsruhe, Germany). The labeled sporozoites
(30,000-100,000/well) were preincubated with different
dilutions of purified scFv (0.5-100 μg/ml) or with the
buffer control for 60 min at RT and thereafter used for
infection of MDBK cells. One day prior the infection, the
wells of 48-well Multidishes (Nunc, Wiesbaden, Ger-
many) were seeded with 50,000 MDBK cells in 400 μl
medium. The cells were allowed to grow for 24 hrs to 60-
80% confluence in DMEM, 10% FCS. After incubation of
antibody-coated sporozoites with the cells at 37°C for 4-
16 hrs, the MDBK cells were washed, detached with
Accutase (PAA Laboratories) and analyzed by flow cytom-
etry using a flow cytometer CyFlow SL (Partec GmbH,
Münster, Germany). The fluorescent free sporozoites asBMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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well as labeled sporozoites in infected cells were detected
at 530 nm. The infected cells, non-infected cells and free
sporozoites were gated using software FloMax (Partec) for
subsequent counting of the infected and non-infected
cells. The deduced percentages of infected cells in pres-
ence/absence of inhibitory antibody were used for calcu-
lation of the inhibition rates as follows:
Generation of recombinant Eimeria antigens
As a source of genetic material, an E. tenella sporozoite
specific cDNA library (λZAP II) [53] was used which was
kindly provided by Dr. Marie Labbe (Laboratoire de Virol-
ogie et Immunologie Moléculaires INRA F 78352, Jouy-
en-Josas, France). A gene encoding a 25 kDa precursor of
a GPI-anchored surface antigen (EtSAG1; original name
TA4 antigen; EMBL accession AJ586531.2) of E. tenella
sporozoites [12] devoid of the signal and GPI-anchor
sequences was amplified by PCR using a forward (sense)
primer, 5'-ATG GTA GGT CTC AGG CCA TGC AGG ATT
ACC CAA CAG CAG T, and a reverse (anti-sense) primer,
5'-ATG GTA GGT CTC AGC GCT GAC TGG AGA AAC TCC
GCC CTT C, and cloned into BsaI-digested pASK-IBA2
expression vector (IBA, Göttingen, Germany). In the gen-
erated plasmid, the EtSAG1 gene was placed under the
transcriptional control of the tetracycline promoter/oper-
ator and was preceded by the OmpA signal sequence for
secretion of the recombinant protein into the bacterial
periplasm. In addition, the expression product contained
a C-terminal Strep-Tactin affinity tag (Strep-tag II) for puri-
fication. Protein expression was induced in E. coli shaking
culture by adding anhydrotetracycline to a final concen-
tration of 200 μg/l. Affinity purification of the recom-
binant EtSAG1 antigen was performed according to the
manufacturer's instruction. Alternatively, PelB leader-
driven periplasmic expression of the 25 kDa EtSAG1 pre-
cursor with the C-terminal His6-tag was achieved using
the bacterial expression vector pSKK3 [54] kindly pro-
vided by Affimed Therapeutics AG (Heidelberg, Ger-
many). For cloning, the EtSAG1 gene was re-amplified
from the previously described pASK-IBA2-based construct
using the primers SAG-NcoI, 5'-ATA TTT CCA TGG CGG
ATT ACC CAA CAG CAG, and SAG-NotI, 5'-ATG GGA
TCC AGC GGC CGC GAC TGG AGA AAC TCC G, and
cloned into NcoI/NotI-digested pSKK3. Bacterial expres-
sion in E. coli RV308, preparation of periplasmic extracts
and antigen isolation by IMAC were performed essentially
as described [55]. Fine purification of the IMAC-enriched
recombinant  EtSAG1 antigen (90-95% purity) was
achieved by anion-exchange chromatography on a Mono
Q 5/50 GL column (GE Healthcare) in 20 mM Tris-HCl,
pH 8.0, with a 0-1 M NaCl linear gradient. Elution frac-
tions of 1 ml were collected and analyzed by SDS-PAGE
followed by Coomassie staining. The fractions containing
most pure target protein were pooled and thoroughly dia-
lyzed against PBS, pH 6.6. The recombinant EtSAG1 anti-
gen was isolated with a yield of 5 mg/l bacterial culture
and purity above 90%. The other seven recombinant anti-
gens of E. tenella used for analyses of specificity of the
library-derived antibody fragments are listed in Addi-
tional file 8. The corresponding genes were retrieved by
PCR using the designed gene-specific primers and cloned
into different bacterial expression vectors (Additional file
8). After sequence verification, expression in bacteria was
performed according to the standard protocols [56] or to
manuals of the corresponding vector manufacturer
(Novagen/Calbiochem-Novabiochem GmbH, Schwal-
bach, Germany; IBA Göttingen GmbH, Göttingen, Ger-
many). Depending on the vector system, the recombinant
antigens were purified either by IMAC or by Strep-Tactin
affinity chromatography.
Analysis of binding properties and antigen specificity of 
selected scFvs
ELISA and Western blot analyses were performed accord-
ing to the standard protocols using oocyst extracts and
recombinant antigens. For IFAT and flow cytometry, spo-
rozoite isolation was performed from freshly passaged
sporulated oocysts. After excystation, the sporozoites were
purified by Percoll density gradient centrifugation [57].
Cryopreservation of sporozoites was carried out as
described [58]. After thawing and washing, the sample
was inspected by light microscopy for the correct number
of parasites. For IFAT, isolated sporozoites of E. tenella
were air dried in Lab-Tek™ Chamber Slides™ (Nunc,
178599). For fluorescent staining of intracellular sporo-
zoites, HepG2 cells [59] were grown in Lab-Tek™ II Cham-
ber Slides™ (Nunc, 154534) overnight followed by
infection with 30,000 sporozoites per chamber for at least
2 hrs. Sporozoites and HepG2 cells, respectively, were
fixed and permeabilized by methanol treatment (90 ml
methanol/10 ml 100 mM MES, 1 mM EGTA, 1 mM
MgCl2, pH 6.9) for 5 min. After blocking for 1 h with 5%
BSA-PBS, the slides were incubated with scFv preparations
(5-20 μg/ml in 5% BSA-PBS, 0.05% Tween-20) for 1 h at
RT. Bound antibody fragments were detected by the Alexa-
555 or -488-conjugated anti-Penta-His antibody (Qiagen)
(1/100 dilution in 5% BSA-PBS, 0.05% Tween-20). After
each antibody incubation, the slides were extensively
washed twice with PBS containing 0.05% Tween-20, and
once with PBS. In addition, the nuclei of HepG2 cells were
stained with DAPI (4',6-diamidin-2'-phenylindoldihy-
drochlorid; Invitrogen; 3 μl 0.02% stock solution per 1 ml
PBS) for 15 min during the final washing procedure. After
removal from the chambers, the glass slides were
mounted with Aqua-Poly/Mount, water-soluble non-flu-
orescing mounting medium (Polysciences Europe GmbH,
Eppelheim, Germany). The specimens were examined
either by phase contrast light microscopy or by fluores-
=× − 100 1 ([ % / %
.  infected cells  infected cells
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cence microscopy with blue light (470-490 nm) using an
Axioplan 2 imaging mot and the AxioCam MR (Carl Zeiss
Jena GmbH, Jena, Germany). For flow cytometry, 50,000-
100,000 sporozoites in each sample were incubated with
the scFv-containing crude periplasmic extracts in dilutions
1/5 - 1/10 in 500 μl DMEM + 2.5% FCS for 1 h at RT. The
sporozoites were washed once with 1 ml PBS, collected by
centrifugation at 2,500 g for 5 min and the scFvs were
detected by an Alexa-488-conjugated anti-Penta-His anti-
body (Qiagen) (1/100 dilution in DMEM + 2.5% FCS).
After incubation for 1 h on ice, the relative fluorescence
intensities were determined using a FACScounter (Partec).
Transient expression of antibody fragments in tobacco 
leaves
The system for transient expression in tobacco was based
on MagnICON™ vectors from Icon Genetics GmbH
(Halle, Germany) [60,61]. For transient expression in
Nicotiana benthamiana, a modified version of the vector
pICH10990 [60] was used. A DNA sequence encoding the
poly-histidine tag was assembled from oligonucleotides
10990HIS1, 5'-CTG TAT ATC TGG ATC CCA TCA CCA
CCA TCA CCA TTA G, and 10990HIS2, 5'-AGC TAA AGC
AAG CTT ACT AAT GGT GAT GGT GGT GAT GGG ATC
CAG, and cloned into the BamHI and HindIII sites of
pICH10990, thus resulting in an intermediate plasmid
pICH-M10990. The scFv genes were amplified by PCR
with gene-specific forward primers (AA28-BsaI, 5'-TTT
GGT CTC AAG GTA TGG CGG AGG TCC AGC TGC AGC
AG; AB09-BsaI, 5'-TTT GGT CTC AAG GTA TGG CGC
AGG TCC AAC TAC AGC; AB28-BsaI, 5'-TTT GGT CTC
AAG GTA TGG CGC AGG TCC AGT TGC AGC; AD10-
BsaI, 5'-TTT GGT CTC AAG GTA TGG CGG AAG TGA
AGC TGG TGG) and universal reverse primer KM2 (5'-
CTT TCC AGA CGT TAG TAA ATG), digested with BsaI and
BamHI and cloned into the pICH-M10990 vector. The
resulting constructs pICH-M1990-AA28, -AB09, -AB21, -
AB28, -AD10 were used for transformation of Agrobacte-
rium tumefaciens strain GV3101 followed by selection of
transformed agrobacteria on YEB-Carbenicillin-Rifampi-
cillin (YEB-Rif-Carb) dishes. For agrobacteria-infiltration
of the tobacco plants, 200 ml of overnight grown scFv
gene containing Agrobacterium cultures were sedimented
by centrifugation (6,000 g, 3 min) and resuspended in 1 l
of 10 mM MES(pH 5.5), 10 mM MgSO4. The resulting
bacterial suspension was mixed with equal amounts of
two agrobacteria strains transformed with plasmids
pICH14011 (encodes DNA integrase) and pICH10570
(5'-provector for cytosolic expression), respectively, pre-
pared in the same way. Greenhouse-grown plants of N.
benthamiana  were infiltrated by immersing the whole
plant into 3 l of the resulting agrobacteria suspension fol-
lowed by vacuum application (-0.8 bar) for 3 minutes.
The gentle return to atmospheric pressure causes the agro-
bacterial suspension to spread inside the apoplastical sys-
tem. The infiltrated N. benthamiana plants were further
grown in the greenhouse. Maximum product accumula-
tion was observed after 9-12 days, as determined by West-
ern blot analysis of leaf discs. For large scale antibody
production, the leaves of 12 plants (approx. 400 g) were
collected and homogenized in an extraction buffer (50
mM KH2PO4/K2HPO4, 100 mM ascorbic acid) using a
Waring Blender. The homogenate was cleared by filtration
through Miracloth (Calbiochem, San Diego, CA) fol-
lowed by centrifugation at 14,000 g and 4°C for 20 min.
The antibody fragments were isolated from the clear
supernatant by batch incubation with Ni-NTA His-bind
resin (Novagen) and subsequent standard purification
according to protocols from the manufacturer.
Pea plant transformation and expression of scFvs in pea 
seeds
For transformation of pea plants, an expression system
based on the binary vector pPZP200 [62] with a seed spe-
cific promoter, regulation signals from Vicia faba [63-65]
and a 35S terminator of transcription from cauliflower
mosaic virus (CaMV) [66] was used. The key features of
the vector are outlined in Additional file 9. The scFv genes
were cloned into the seed specific expression cassette of
the pPZP200-USP+ plasmid using NcoI and BamHI restric-
tion sites (Additional file 9) followed by electroporation
into strain EHA105 of A. tumefaciens. For transformation,
the fodder pea variety "Eiffel" was chosen. Pea transfor-
mation was carried out as described [67] with modifica-
tions [36]. In brief, immature pods were sterilized in 70%
(v/v) ethanol (1 min) followed by 1% (w/v) sodium
hypochlorite (20 min) and three washes with sterile dis-
tilled water. Seeds were removed from the pods and the
outer coats (testae) of the seeds were excised. Coatless
seeds were pre-cultivated for 1 day in liquid B5h medium
[68]. For preparation of explants, the root end of each seg-
ment was cut off and the epicotyl and the apical meristem
regions were sliced transversely into 3-5 segments. Seg-
ments were then fully immersed in the agrobacterial sus-
pension (108 cells/ml) for 30 to 40 min. The suspension
comprised two strains of transformed Agrobacterium, one
carried the plasmid pPZP200-USP-scFv (see above) and
the second one contained a binary vector pPZP-bar with
the marker gene bar  encoding phosphinotricin acetyl-
transferase (PAT), which confers resistance to glu-
phosinate ammonium (herbicide Basta). Wet segments
were plated on B5h medium and cultured at 21°C for 3-4
days with a 16 h photoperiod. After co-cultivation,
explants were washed three to four times with sterile
water. The callus induction medium and the shoot devel-
opment were as described by Schroeder et al. [67]. When
the developing shoots reached over 20 mm in length, they
were grown on 10 mg/L phosphinotricin for some days.
Resistant shoots were grafted onto the root stock of "Eif-
fel" seedlings in vitro. After 6-10 days, the plants were
adapted to soil and grown up in a climatic chamber.
When primary transformants (F0) developed to a stage ofBMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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4-6 normal nodes, leaflets were painted with a 0.5% (v/v)
watery solution of Basta (Sanofi-Aventis) on the upper
side to determine the bar transgenic plants. Integration of
the scFv transgene was checked by PCR in leaflet extracts
using the primers scf-uni-up, 5'-AAA TTC ACC TTC TTC
AAG C, and USP-do, 5'-AGG TGC ATG AAC GTC ACG
TGG. The F0 plants were allowed to self-pollinate and 10-
20 seeds were analyzed for presence of the scFv gene by
PCR and for expression of the scFv protein by SDS-PAGE
and Western blot analysis. Using segregation analysis for
both scFv and bar genes, non-coupled single insert lines
for the scFv gene were determined. From all progeny of a
single insert line, with the out-segregated bar gene, the
homozygous state of the scFv gene was tested in the next
(F2) generation. Thus, co-transformation of both the bar
and the scFv gene allowed selection of transgenic plants
with no resistance (bar) gene. For estimation of the expres-
sion levels, the scFv antibody fragments were isolated
from the pea seeds and purified. For isolation of the
recombinant protein, the pea seeds were ground using a
ball mill and the resulting pea flour was suspended in ice-
cold extraction buffer containing 50 mM Tris-HCl, 300
mM NaCl, 0.2% Tween-20, pH 7.4, at a ratio of 1/20 (w/
v). Extraction was performed at 4°C in three steps. After
each step, the samples were centrifuged at 30,000 g and
4°C for 30 min. The supernatants were pooled and sub-
jected to IMAC on Ni-NTA His-bond resin (Novagen)
using the extraction buffer as loading and elution buffer,
in the latter case supplemented with 500 mM imidazole.
The target protein was further purified using IEC and ana-
lyzed, as mentioned earlier for bacterial and tobacco scFv
expression. Purified scFv was used as a standard for the
quantification of antibody expression in pea seeds by
ELISA using Eimeria oocyst extract as an antigen. Titration
of scFv standard generated a calibration curve from which
the amounts of active antibody in diluted pea seed
extracts were deduced. Extracts from the pea seeds express-
ing scFv AB28 were prepared by grinding the seeds in a
ball mill followed by soluble protein extraction from a
defined amount of the powder in PBS containing 1 mM
PMSF. As a negative control, extracts from wild-type pea
seeds prepared in the same way were used. Clear superna-
tants were applied to an ELISA plate in serial dilutions.
Detection was performed using anti-penta-His antibody
(Qiagen) followed by HRP-conjugated anti-mouse IgG
(Sigma) and TMB as a substrate. Data were analyzed using
the software Prism (GraphPad, San Diego, CA). The purity
of the scFv standard, as determined by scanning a
Coomassie-stained SDS-PAA gel, was considered in the
calculations.
Analysis of the proteolytic and pH stability in vitro
For analyses of the pH stability, commercially available
standard buffers of pH 2-11 (Roth, Karlsruhe, Germany)
were used. Analyses were performed by ELISA using plates
coated with the diluted extract from E. tenella oocysts (0.4
μg/well). In the binding assays, the antibody fragments
were diluted in buffers with different pH, applied to the
antigen-coated ELISA plate and incubated for 1 h at RT.
For dissociation analyses, the antibody samples were
applied in PBS/2% BSA, pH 6.6, and after incubation (1 h
at RT) and washing the buffer solution of a defined pH
was added followed by 1 h incubation. In all cases, the
bound antibody fragments were detected using anti-
penta-His antibody (Qiagen). For measuring the proteo-
lytic stability, an "In vitro true digestibility" protocol from
Ankom Technology (Macedon, NY) was used. For the
experiments, chyme was taken from the small intestine of
chickens, cleared by centrifugation and the resultant intes-
tinal fluid was stored in aliquots at -80°C. Before start of
the experiment, buffer solutions A and B were prepared
according to the following recipes. The buffer solution A
comprised 10 g/l KH2PO4, 0.5 g/l MgSO4 × 7H2O, 0.5 g/l
NaCl, 0.1 g/l CaCl2 × 2H2O and 0.5 g/l urea (reagent
grade). Respectively, the buffer solution B contained 15.0
g/l Na2CO3 and 1.0 g/l Na2S × 9H2O. The buffer solutions
A and B were pre-warmed to 39°C and mixed in a ratio of
5/1 to obtain pH 6.8. No further pH adjustment was nec-
essary. The resulting buffer AB was used to prepare a series
of 1/2 dilutions of the chicken intestinal fluid. The anti-
body fragments were incubated with the dilutions of
intestinal fluid at 37°C for 30 min on a rocking platform.
The residual antigen-binding activity was measured by
ELISA using plates coated with oocyst extract of E. tenella.
In addition, protein degradation was monitored by SDS-
PAGE followed by Coomassie staining and by Western
blot analysis with the anti-His-tag detection. For quantifi-
cation of the results, the ED50 values (effective dilution
leading to 50% loss of activity) were deduced from the sig-
moid ELISA curves [log(intestinal fluid dilution) vs.
response (% maximal binding)] by fitting them using a
standard slope model of software Prism (GraphPad).
Force-feeding animal trials
Studies were performed using 10-day old non-sexed com-
mercial Lohmann broiler chickens (type Ross) with an
approx. weight of 100 g randomly divided into groups of
3-30 individuals (the cohort size varied in different stud-
ies). The chickens were orally infected with a single dose
of E. tenella freshly prepared oocysts (20-500 oocysts per
bird depending on the study). Force-feeding started one
day before infection and continued for 8 consecutive days.
Birds in the treatment groups received either 1 mg scFv
isolated from tobacco leaves or transgenic pea seed flour
in 1 ml PBS a day via gavage. The chickens were force-fed
three times daily. The maximum dose of pea seeds which
could be safely administered to a 10-day old chicken was
empirically determined as one pea seed a day or 1/3 peaBMC Biotechnology 2009, 9:79 http://www.biomedcentral.com/1472-6750/9/79
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seed per administration. The pea flour was prepared from
the antibody containing seeds using a ball mill and was
suspended in phosphate buffer just before force-feeding.
Based on the activity measurements in ELISA, the AB28
antibody content in pea seed was calculated as 1.76 g
scFv/kg seeds. Assuming the average weight of a pea seed
as 0.3 g, the pea flour-fed birds received the maximal pos-
sible dose of 0.5 mg antibody per day (half the amount of
administered purified scFv). As positive controls of infec-
tion, two animal groups were treated with the same quan-
tities of material comprising the irrelevant BA11 antibody,
either in the form of pea flour or as a soluble antibody iso-
lated from the tobacco leaves. The negative control of
infection group received heat inactivated oocysts. For
comparison of anti-coccidial effect, one group received 1
ml of a 2.5% solution of the anti-coccidial drug Baycox®
(Bayer HealthCare) in water. Baycox® is currently used to
control Eimeria in commercial poultry farming. The treat-
ment started one day before the infection and continued
for 14 consecutive days. For all animals, fecal samples
were collected before infection (to show whether the ani-
mals were already infected before the start of the experi-
ment) and daily after infection. The oocyst counts were
determined in all individual fecal samples and each sam-
ple was counted six times by two different persons. In
addition, the chicken weights were controlled and
recorded. At the end of each study, all birds were sacrificed
and weighted according to the protocol. One individual
of each group was subjected to necropsy. As measures of
infection outcome, the sum of shed oocyst numbers at
days of maximum oocyst release, 7 and 8 p.i., were used.
To illustrate the specific effect of the anti-Eimeria treat-
ment, the percentage of infection inhibition was calcu-
lated according to the following formula:
Ad libitum feeding trials
In a preliminary feeding experiment, twenty 9-day-old
chickens were fed with normal feed (n = 10) and with the
feed premixed with 10% BA11-transgenic pea shred (n =
10) for 8 days. The feed was weighed and reweighed every
day, the body weight was recorded and the feces were col-
lected on feeding days 3 and 7. The antibody content in
the fodder and in feces was controlled by the BA11-spe-
cific ELISA. In a high infection dose model, the broiler
chickens were orally infected with individual doses of
2,500 freshly prepared oocysts. Three treatment cohorts
were formed; each comprising 5-30 individually housed
ten-day old chickens with average weight of 127.5 g. For
feeding, the usual chicken fodder was mixed with 10%
pea shred derived either from AB28-expressing seeds
(treatment group, n = 30) or from the wild-type pea (pos-
itive control of infection, n = 25). For shredding, the pea
seeds were coarsely ground with a centrifugal mill ZM
1000 (Retsch, Haan, Germany). The negative control
group (control of spontaneous infection) comprised 5
birds which were not infected and received conventional
fodder. Feeding started one day before the infection and
continued for eight consecutive days. Adapted from the
preliminary feeding experiment, the mean consumption
of the scFv antibody was calculated as 35.63 mg antibody/
kg body weight × day (Additional file 7). On the seventh
day p.i., the chickens were sacrificed and the caecal lesion
scores and the oocyst counts in caeca and feces were deter-
mined. The low infection dose model was designed to
mimic the real situation in the barns for rearing commer-
cial broilers where the chickens are spontaneously
infected with the relatively low dosages of Eimeria oocysts.
In this case, the feeding experiment was repeated under
the same conditions, however, with the ten-fold lower
infection doses, i.e. 250 oocysts per bird.
Statistical analysis
Data analyses were performed using the software Prism
(GraphPad). All data were expressed as means ± SEM val-
ues. Comparisons of the mean values were performed
between the control and treatment groups using a one-tail
unpaired t-test.
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